AOMS1
MCID: ABD014
MIFTS: 64

Abdominal Obesity-Metabolic Syndrome 1 (AOMS1)

Categories: Blood diseases, Cardiovascular diseases, Endocrine diseases, Genetic diseases, Metabolic diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Abdominal Obesity-Metabolic Syndrome 1

MalaCards integrated aliases for Abdominal Obesity-Metabolic Syndrome 1:

Name: Abdominal Obesity-Metabolic Syndrome 1 57 11 14
Metabolic Syndrome X 57 11 75 28 53 71
Metabolic Syndrome 43 63 38 16 75
Abdominal Obesity Metabolic Syndrome 71
Dysmetabolic Syndrome X 11
Metabolic Disease 16
Aoms1 57

Characteristics:


Inheritance:

Autosomal dominant 57

Classifications:



External Ids:

Disease Ontology 11 DOID:14221
OMIM® 57 605552
OMIM Phenotypic Series 57 PS605552
ICD9CM 34 277.7
MeSH 43 D024821
NCIt 49 C84442
SNOMED-CT 68 190394009
MedGen 40 C4552048
SNOMED-CT via HPO 69 24184005 248311001 38341003
UMLS 71 C0524620 C2930930

Summaries for Abdominal Obesity-Metabolic Syndrome 1

OMIM®: 57 A clustering of abdominal obesity, high triglycerides, low levels of high density lipoprotein cholesterol (HDLC), high blood pressure, and elevated fasting glucose levels is sometimes called metabolic syndrome X (Reaven, 1988) or abdominal obesity-metabolic syndrome (Bjorntorp, 1991). The syndrome may affect nearly 1 in 4 U.S. adults and is considered a veritable epidemic (Ford et al., 2002). It is a major risk factor for both diabetes mellitus (see 125853 and Haffner et al., 1992) and cardiovascular disease (Isomaa et al., 2001). The etiology is complex, determined by the interplay of both genetic and environmental factors. The prevalence varies substantially among ethnic groups, with the highest rates in Mexican American women (Park et al., 2003). Other factors influencing the metabolic syndrome include age, smoking, alcohol, diet, and physical inactivity. (605552) (Updated 08-Dec-2022)

MalaCards based summary: Abdominal Obesity-Metabolic Syndrome 1, also known as metabolic syndrome x, is related to nutritional deficiency disease and hyperlipidemia, familial combined, 3, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Abdominal Obesity-Metabolic Syndrome 1 is MIR122 (MicroRNA 122), and among its related pathways/superpathways are Metabolism and IL-9 Signaling Pathways. The drugs Cilostazol and Vildagliptin have been mentioned in the context of this disorder. Affiliated tissues include heart, liver and adipocyte, and related phenotypes are hypertension and abdominal obesity

PubMed Health : 63 Metabolic syndrome: Metabolic (met-ah-BOL-ik) syndrome is the name for a group of risk factors that raises your risk for heart disease and other health problems, such as diabetes and stroke. The term "metabolic" refers to the biochemical processes involved in the body's normal functioning. Risk factors are traits, conditions, or habits that increase your chance of developing a disease. In this article, "heart disease" refers to coronary heart disease (CHD). CHD is a condition in which a waxy substance called plaque (plak) builds up inside the coronary (heart) arteries. Plaque hardens and narrows the arteries, reducing blood flow to your heart muscle. This can lead to chest pain, a heart attack, heart damage, or even death.

Disease Ontology: 11 An abdominal obesity-metabolic syndrome characterized by insulin resistance and hyperinsulinemia, dyslipidemia, essential hypertension, abdominal obesity, glucose intolerance or noninsulin-dependent diabetes mellitus and an increased risk of cardiovascular events.

Wikipedia: 75 Metabolic syndrome is a clustering of at least three of the following five medical conditions: abdominal... more...

Related Diseases for Abdominal Obesity-Metabolic Syndrome 1

Diseases in the Abdominal Obesity-Metabolic Syndrome 1 family:

Abdominal Obesity-Metabolic Syndrome 3 Abdominal Obesity-Metabolic Syndrome 4

Diseases related to Abdominal Obesity-Metabolic Syndrome 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1495)
# Related Disease Score Top Affiliating Genes
1 nutritional deficiency disease 31.7 RETN LEP IGFBP1 ADIPOQ
2 hyperlipidemia, familial combined, 3 31.6 PPARA LPL INS APOB ADIPOQ
3 hypolipoproteinemia 31.6 MTTP MIR33A LPL APOB
4 arteries, anomalies of 31.5 MIR33A MIR122 INS APOB ADIPOQ
5 apnea, obstructive sleep 31.5 RETN LEP INS GCG ADIPOQ
6 cerebrovascular disease 31.3 MEG3 LPL INS APOB
7 chronic kidney disease 31.3 LPL LEP INS IGFBP1 APOB ADIPOQ
8 acquired metabolic disease 31.3 SLC2A4 SERPINE1 RETN PPARG PPARA MIR33A
9 fatty liver disease 31.3 SERPINE1 SCD RETN PPARG PPARA MTTP
10 peripheral vascular disease 31.3 SERPINE1 INS APOB
11 abdominal obesity-metabolic syndrome quantitative trait locus 2 31.2 SLC2A4 SERPINE1 PPARG PPARD PPARA LEP
12 sleep apnea 31.2 SERPINE1 RETN PPARG LEP INS APOB
13 hyperlipoproteinemia, type i 31.2 MTTP LPL APOB
14 liver disease 31.2 RETN PPARG PPARA MTTP MIR122 MEG3
15 adult syndrome 31.2 SLC2A4 PPARG PPARA LEP INS ADIPOQ
16 acanthosis nigricans 31.2 SLC2A4 LEP INS ADIPOQ
17 pre-eclampsia 31.1 SERPINE1 LEP INS IGFBP1 ADIPOQ
18 kidney disease 31.1 SERPINE1 RETN PPARG LEP INS IGFBP1
19 turner syndrome 31.1 LEP INS IGFBP1
20 lipoprotein quantitative trait locus 31.0 SERPINE1 RETN PPARG PPARA LPL INS
21 hyperandrogenism 31.0 RETN PPARG INS IGFBP1 HSD11B1 ADIPOQ
22 sleep disorder 31.0 LEP INS ADIPOQ
23 hypothyroidism 31.0 SERPINE1 RETN LPL LEP INS APOB
24 non-alcoholic steatohepatitis 30.9 SCD PPARG PPARA MTTP MIR122 LEP
25 coronary stenosis 30.9 SERPINE1 LPL APOB
26 acne 30.9 PPARG LEP INS
27 arteriosclerosis 30.9 SERPINE1 PPARG PPARA INS APOB ADIPOQ
28 anovulation 30.8 LEP INS IGFBP1
29 eating disorder 30.8 RETN LEP INS
30 amenorrhea 30.8 LEP INS ADIPOQ
31 gestational diabetes 30.8 SLC2A4 RETN PPARG LEP INS IGFBP1
32 skin disease 30.8 SCD PPARG PPARD PPARA MIR33A MIR122
33 insulin-like growth factor i 30.7 LEP INS IGFBP1
34 mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome 30.7 INS ADIPOQ
35 endometrial cancer 30.7 SERPINE1 PPARG MEG3 LEP INS IGFBP1
36 hypopituitarism 30.6 LEP INS HSD11B1
37 liver cirrhosis 30.6 SLC2A4 RETN MIR122 MEG3 LEP INS
38 myocardial infarction 30.6 SERPINE1 RETN PPARG PPARA LPL LEP
39 aortic atherosclerosis 30.6 LPL INS APOB
40 hyperthyroidism 30.6 RETN LEP INS ADIPOQ
41 hypoalphalipoproteinemia 30.6 PPARA LPL APOB
42 nonobstructive coronary artery disease 30.6 INS APOB ADIPOQ
43 hypertriglyceridemia 1 30.5 SERPINE1 LPL INS APOB
44 peripheral nervous system disease 30.5 PPARG MIR122 LEP INS GCG
45 hypoglycemia 30.5 SLC2A4 LEP INS IGFBP1 GCG ADIPOQ
46 familial hypercholesterolemia 30.5 SERPINE1 MTTP LPL INS APOB
47 hypercholesterolemia, familial, 1 30.4 LPL INS APOB
48 type 1 diabetes mellitus 30.3 MEG3 LPL LEP INS IGFBP1 GCG
49 familial partial lipodystrophy 30.3 PPARG PPARA LPL LEP INS ADIPOQ
50 acute pancreatitis 30.3 RETN LPL INS

Graphical network of the top 20 diseases related to Abdominal Obesity-Metabolic Syndrome 1:



Diseases related to Abdominal Obesity-Metabolic Syndrome 1

Symptoms & Phenotypes for Abdominal Obesity-Metabolic Syndrome 1

Human phenotypes related to Abdominal Obesity-Metabolic Syndrome 1:

30
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hypertension 30 HP:0000822
2 abdominal obesity 30 HP:0012743

Symptoms via clinical synopsis from OMIM®:

57 (Updated 08-Dec-2022)
Cardiovascular Vascular:
hypertension

Laboratory Abnormalities:
elevated fasting glucose levels

Growth Weight:
abdominal obesity

Clinical features from OMIM®:

605552 (Updated 08-Dec-2022)

UMLS symptoms related to Abdominal Obesity-Metabolic Syndrome 1:


angina pectoris; chest pain; edema

MGI Mouse Phenotypes related to Abdominal Obesity-Metabolic Syndrome 1:

45 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 liver/biliary system MP:0005370 10.39 ADIPOQ APOB HSD11B1 IGFBP1 INS LEP
2 homeostasis/metabolism MP:0005376 10.33 ADIPOQ APOB GCG HSD11B1 INS LEP
3 muscle MP:0005369 10.29 ADIPOQ APOB HSD11B1 INS LEP LPL
4 growth/size/body region MP:0005378 10.24 ADIPOQ APOB GCG HSD11B1 INS LEP
5 adipose tissue MP:0005375 10.21 ADIPOQ HSD11B1 INS LEP LPL PPARA
6 renal/urinary system MP:0005367 10.1 ADIPOQ GCG INS LEP PPARA PPARG
7 cellular MP:0005384 10.1 ADIPOQ APOB HSD11B1 IGFBP1 INS LEP
8 immune system MP:0005387 10.03 ADIPOQ APOB HSD11B1 IGFBP1 INS LEP
9 cardiovascular system MP:0005385 10 ADIPOQ APOB HSD11B1 INS LEP LPL
10 mortality/aging MP:0010768 9.8 ADIPOQ APOB GCG INS LEP LPL
11 integument MP:0010771 9.32 ADIPOQ HSD11B1 INS LEP LPL PPARA

Drugs & Therapeutics for Abdominal Obesity-Metabolic Syndrome 1

PubMed Health treatment related to Abdominal Obesity-Metabolic Syndrome 1: 63

Healthy lifestyle changes are the first line of treatment for metabolic syndrome . Lifestyle changes include losing weight, being physically active, following a heart healthy diet, and quitting smoking . If lifestyle changes aren't enough, your doctor may prescribe medicines. Medicines are used to treat and control risk factors such as high blood pressure , high triglycerides , low HDL cholesterol , and high blood sugar . Blood -thinning medicines, such as aspirin , also may be used to reduce the risk of blood clots. Excessive blood clotting is a condition that often occurs with metabolic syndrome .

Drugs for Abdominal Obesity-Metabolic Syndrome 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 615)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
2
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
3
Captopril Approved Phase 4 62571-86-2 44093
4
Perindopril Approved Phase 4 82834-16-0, 107133-36-8 107807
5
Lactitol Approved, Investigational Phase 4 585-86-4 157355
6
Metyrapone Approved, Investigational Phase 4 54-36-4 4174
7
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
8
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
9
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
10
Titanium dioxide Approved Phase 4 13463-67-7
11
Testosterone Approved, Investigational Phase 4 58-22-0 5408 6013
12
Ezetimibe Approved Phase 4 163222-33-1 150311
13
Plasminogen Approved Phase 4 9001-91-6
14
Ramipril Approved Phase 4 87333-19-5 5362129
15
Heparin, bovine Approved, Investigational, Withdrawn Phase 4 9005-49-6 22833565 9812414 772
16
Nifedipine Approved Phase 4 21829-25-4 4485
17
Acetylsalicylic acid Approved, Vet_approved Phase 4 50-78-2 2244
18
Nitric Oxide Approved Phase 4 10102-43-9 145068
19
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
20
Moxifloxacin Approved, Investigational Phase 4 186826-86-8, 354812-41-2, 151096-09-2 152946
21
Methyltestosterone Approved Phase 4 58-18-4 6010
22
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0 21873174 65157
23
Testosterone enanthate Approved Phase 4 315-37-7 9416
24
Olmesartan Approved, Investigational Phase 4 144689-63-4, 144689-24-7 158781 130881
25
Galantamine Approved Phase 4 357-70-0, 1953-04-4 9651
26
Simvastatin Approved Phase 4 79902-63-9 54454
27
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
28
Nebivolol Approved, Investigational Phase 4 152520-56-4, 99200-09-6, 118457-14-0 71301
29
Pitavastatin Approved Phase 4 147511-69-1 5282452
30
Infliximab Approved Phase 4 170277-31-3
31
Ranolazine Approved, Investigational Phase 4 142387-99-3, 95635-55-5 56959
32
Clozapine Approved Phase 4 5786-21-0 2818 135398737
33
Sodium citrate Approved, Investigational Phase 4 68-04-2 23431961
34
Atenolol Approved Phase 4 29122-68-7 2249
35
Bisoprolol Approved Phase 4 66722-44-9 2405
36
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
37
Sildenafil Approved, Investigational Phase 4 139755-83-2, 171599-83-0 5212 135398744
38
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
39
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
40
Flupentixol Approved, Investigational, Withdrawn Phase 4 2709-56-0 25137855 5281881 17012
41
Febuxostat Approved Phase 4 144060-53-7 134018
42
Verapamil Approved Phase 4 152-11-4, 52-53-9 2520
43
Trandolapril Approved Phase 4 87679-37-6 5484727
44
Inositol Approved, Investigational, Withdrawn Phase 4 87-89-8
45
Histamine Approved, Investigational Phase 4 51-45-6 774
46
Doxazosin Approved Phase 4 74191-85-8 3157
47
Isosorbide dinitrate Approved, Investigational Phase 4 87-33-2 3780 6883
48
Isosorbide Approved, Investigational Phase 4 652-67-5 99937 12597
49
Oseltamivir Approved Phase 4 204255-11-8, 196618-13-0 65028
50 English walnut Approved Phase 4

Interventional clinical trials:

(show top 50) (show all 1799)
# Name Status NCT ID Phase Drugs
1 Effects of Cilostazol on Plasma Adipocytokine and Arterial Stiffness in Type 2 Diabetes Patient With Metabolic Syndrome (Randomized, Double-Blind, Placebo-Controled, Cross-Over Study) Unknown status NCT00573950 Phase 4 cilostazol;Placebo
2 The Effect of Testim and Training in a Population Based, Randomized, Placebo-controlled, Double-blinded Study of Hypogonadal Men Unknown status NCT00700024 Phase 4 Testim;placebo
3 Comparative Effecacy of Metformin and Vildagliptin on Cardiometabolic Risk Factors, Metabolic Syndrome, and Diabetic Nephropathy Progression Unknown status NCT04485845 Phase 4 Vildagliptin;Captopril Tablets;MetFORMIN 500 Mg Oral Tablet
4 Effects of the Continuous Positive Airway Pressure Ventilation on the Prevalence of the Metabolic Syndrome and Cardiac Morpho-Functional Characteristics in Sleep Apnea Syndrome Unknown status NCT00517777 Phase 4
5 The Monitor of Serum Prolactin Level and Related Clinical Observations Among Individuals With Schizophrenia Spectrum Illnesses in a 3 Months Aripiprazole Trial Unknown status NCT00468533 Phase 4 Aripiprazole
6 Open-Label Non-Comparative Study of the Effects of a Combination Antihypertensive Treatment With Moxonidine + Perindopril in Hypertensive Patients With Metabolic Syndrome Unknown status NCT04023565 Phase 4 perindopril + moxonidine
7 The Effects of Cortisol Blockade on Nutritional Sympathetic Nervous System Responsiveness in Overweight and Obese Subjects With Metabolic Syndrome Unknown status NCT01620684 Phase 4 metyrapone;placebo
8 The Cardiovascular Effects of Febuxostat and Benzbromarone on Left Ventricle Diastolic Dysfunction in Individuals With Metabolic Syndrome and Hyperuricemia - an Open-label Non-blinded Randomized-controlled Clinical Trial Unknown status NCT03534037 Phase 4 Febuxostat 40 mg;Benzbromarone 50mg
9 Effects of Growth Hormone on Body Fat Distribution, Insulin Action and Cardiovascular Risk Factors in Middle-Aged Men With Metabolic Syndrome Unknown status NCT00307411 Phase 4 Growth hormone
10 Effect of Vitamin D on Metabolic Parameters in Patients With the Metabolic Syndrome Unknown status NCT01237769 Phase 4 Vitamin D3
11 Effects of Metformin on Cardiovascular Risk Factors in Postmenopausal Women With Metabolic Syndrome Unknown status NCT01342744 Phase 4 Metformin;Placebo
12 Ranolazine, Ethnicity and the Metabolic Syndrome - REMS Study Unknown status NCT01304095 Phase 4 Ranolazine
13 The ACT-OUT Trial: ACTivity OUTcomes Based on the Consumption of a High Carbohydrate or High Fat Diet in Patients With Metabolic Syndrome Unknown status NCT01357382 Phase 4
14 the Long-term Effects of High-doSe pitavaStatin on Diabetogenicity in Comparison With Atorvastatin in Patients With Metabolic Syndrome (LESS-DM) Randomized Clinical Trial Unknown status NCT02940366 Phase 4 Pitavastatin 4 mg orally daily;Atorvastatin 20 mg orally daily
15 A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF THE SUPPLEMENTATION WITH KIOLIC® IN PATIENTS WITH DIAGNOSIS OF METABOLIC SYNDROME TO IMPROVE ENDOTHELIAL FUNCTION AND INFLAMMATORY STATE. "KYMES" Unknown status NCT01168700 Phase 4 aged garlic extract;Placebo
16 Effects of Valsartan on Metabolic Syndrome in Patients With Hypertension Unknown status NCT00790946 Phase 4 Valsartan
17 Efficacy and Safety of Lobeglitazone Versus Sitagliptin in Inadequately Controlled by Metformin Alone Type 2 Diabetes Mellitus Patients With Metabolic Syndrome: 24-week, Multi-center, Randomized, Double-blind, Phase 4 Study Unknown status NCT02480465 Phase 4 Lobelitazone 0.5mg;Sitagliptin 100mg
18 A Multi-center, Open-label, Single-arm, Phase IV Clinical Trial to Evaluate the Preference Regarding Convenience of Medication, Efficacy and Safety After Switching to SUGAMET®XR Tablet 5/1000mg in Patients With Type 2 Diabetes and Renal Diseases Unknown status NCT04653779 Phase 4 Evogliptin 5mg/Metformin 1000mg
19 Comparison of Oral 30 % Dextrose and iv Midazolam Sedation During MRI in Neonates Unknown status NCT02645279 Phase 4 IV midazolam
20 A 6-week, Randomised, Open-label, Parallel Group, Multi-centre Study to Compare the Efficacy of Rosuvastatin 10mg With Atorvastatin 10mg in the Treatment of Metabolic Syndrome Subjects With Raised LDL-C Completed NCT00395486 Phase 4 Rosuvastatin;Atorvastatin
21 The Effects of Night-time Versus Morning Administration of Eplerenone on the Diurnal Variation of Plasminogen Activator Inhibitor-1 Completed NCT00515021 Phase 4 Eplerenone (Morning);Eplerenone (Night-time)
22 The Metabolic Syndrome in Patients With Schizophrenia Completed NCT00338949 Phase 4 Switch;Control
23 A Multi-Center, Double-Blind, Randomized, Superiority Clinical Study to Compare the Effects of Cilnidipine on Metabolic Syndrome Improvement With Nifedipine GITS in Hypertensive Patients With Metabolic Syndrome (Phase IV) [SLIMS] Completed NCT00325936 Phase 4 Cilnidipine
24 Study of Niacin and Rosiglitazone in Dysmetabolic Dyslipidemia Completed NCT00304993 Phase 4 fenofibrate;niacin;rosiglitazone
25 PROCLAIM: Pilot Study Examining Effects of Clopidogrel Compared to Placebo on Markers of Inflammation in Subjects With Metabolic Syndrome Completed NCT00296803 Phase 4 clopidogrel
26 A Randomized, Double-Blind Trial to Test Higher- Versus Lower-Doses of Aspirin on Inflammatory Markers and Platelet Biomarkers and Nitric Oxide Formation in High Risk Primary Prevention (Patients With Metabolic Syndrome) Completed NCT00272311 Phase 4 Aspirin
27 A Phase IV Study, Prospective, Randomised, Open Label, Blinded Endpoint, Parallel Group, 9 Weeks of Comparison Between Oral Administration of Telmisartan Tablet (80mg Once Daily) and Amlodipine Tablet (10 mg Once Daily) on Biological PPAR Gamma Activities in Non Controlled Hypertensive Male Patients With Metabolic Syndrome Completed NCT00242814 Phase 4 Micardis;Amlodipine
28 The Effects of Aripiprazole on Patients With "Metabolic Syndrome": An Open-Label Trial Completed NCT00224822 Phase 4 Aripiprazole
29 Oral Contraceptives in the Metabolic Syndrome Completed NCT00205504 Phase 4 Ortho Tri Cyclen
30 Effect of Sitagliptin on the Blood Pressure Response to ACE Inhibition in the Metabolic Syndrome Completed NCT00666848 Phase 4 Placebo;Enalapril 5mg;Enalapril 10mg;Sitagliptin
31 Effects of Cholinergic Stimulation on Visceral Fat, Oxidative Stress and Inflammatory Markers in Patients With Metabolic Syndrome: a Randomized Clinical Trial Completed NCT02283242 Phase 4 Galantamine;Placebo (for galantamine)
32 Effect of Testosterone Replacement on Insulin Resistance in Hypogonadal, Non-obese Men With Metabolic Syndrome Completed NCT00487734 Phase 4 Placebo for testosterone gel
33 Effect of Growth Hormone Replacement Therapy on Cardiovascular Risk Factors in Adult Patients With Severe Growth Hormone Deficiency: Association With IGF-I Concentration Completed NCT01877512 Phase 4 Change in daily dosage of Growth Hormone
34 Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus and South Asian Descent Completed NCT02660047 Phase 4 Liraglutide;Liraglutide - Placebo
35 The Effects of Ezetimibe/Simvastatin Versus Simvastatin Alone on Platelet and Inflammatory Biomarkers in Patients With the Metabolic Syndrome Completed NCT00819403 Phase 4 simvastatin;ezetimibe/simvastatin
36 Comparative Effect of Nebivolol vs. Metoprolol on Insulin Sensitivity and Fibrinolytic Balance in Metabolic Syndrome Completed NCT00775671 Phase 4 placebo;Nebivolol;Metoprolol
37 Endogenous Opioid Activity and Affective State in Insulin Resistant Women Completed NCT02069379 Phase 4 Metformin;Placebo
38 Impact of Obstructive Sleep Apnea Treatment in Patients With Metabolic Syndrome: A Randomized Study Completed NCT02295202 Phase 4
39 A Pilot Study Exploring the Efficacy and Safety of Herbal Medicine on Korean Obese Women With Metabolic Syndrome Risk Factors - Double Blinded, Randomized, Multicenter, Placebo Controlled Clinical Trial - Completed NCT02651454 Phase 4 Daesiho-tang;Chowiseungcheng-tang;Placebo
40 Endogenous Renin-Angiotensin-Aldosterone System and Glucose Metabolism Completed NCT02034435 Phase 4 Epleronone;Amlodipine
41 Diet, Obesity and Genes Completed NCT00390637 Phase 4
42 The Effect Of Fluvastatin XL® Treatment On The Lipid Profile In Patients With Metabolic Syndrome Completed NCT00664742 Phase 4 Fluvastatin XL®
43 A Prospective Comparative Clinical Study to Identify Efficacy and Safety of Pitavastatin in Patients With a Metabolic Syndrome Completed NCT00640276 Phase 4 pitavastatin
44 A Prospective Trial of Anti-TNF-Alpha Chimeric Monoclonal Antibody (Infliximab, Remicade®) on Insulin Sensitivity, Beta Cell Function and Cardiovascular Risk Profile in Insulin Resistant Human Obesity Completed NCT00636142 Phase 4
45 The Mesoglycan and Vascular Reactivity in the Metabolic Syndrome Completed NCT02254850 Phase 4 Mesoglycan;Placebo
46 Pioglitazone for the Treatment of Bipolar Disorder and Comorbid Metabolic Syndrome or Insulin Resistance Completed NCT00835120 Phase 4 Pioglitazone
47 Multicenter,Double Blind,Randomized, 2-period, Crossover Study to Compare Ezetimibe/Simvastatin (10mg/10 mg) Combination Tablet Versus Simvastatin 80mg Tablet on Postprandial Arterial Endothelial Function in Patients With Metabolic Syndrome Completed NCT00817843 Phase 4 Simvastatin;Simvastatin/Ezetimibe
48 Open-labelled, Single Arm, Phase IV Clinical Study to Evaluate the Impact of Rosuvastatin on Lipid Levels in Patients With Metabolic Syndrome (EFFORT) Completed NCT00815659 Phase 4 rosuvastatin
49 Multicenter Study for Anti-oxidative and Anti-inflammatory Effects of Pitavastatin in Hypercholesterolemic Patients With Metabolic Syndrome Completed NCT00444717 Phase 4 pitavastatin
50 Impact of Ranolazine on Inflammatory, Thrombogenic, Lipogenic, Biomarkers in Women With Angina and Metabolic Syndrome. Completed NCT02252406 Phase 4 Ranolazine

Search NIH Clinical Center for Abdominal Obesity-Metabolic Syndrome 1

Cochrane evidence based reviews: metabolic syndrome

Genetic Tests for Abdominal Obesity-Metabolic Syndrome 1

Genetic tests related to Abdominal Obesity-Metabolic Syndrome 1:

# Genetic test Affiliating Genes
1 Metabolic Syndrome X 28 MTTP

Anatomical Context for Abdominal Obesity-Metabolic Syndrome 1

Organs/tissues related to Abdominal Obesity-Metabolic Syndrome 1:

MalaCards : Heart, Liver, Adipocyte, Endothelial, Skeletal Muscle, Ovary, Spinal Cord

Publications for Abdominal Obesity-Metabolic Syndrome 1

Articles related to Abdominal Obesity-Metabolic Syndrome 1:

(show top 50) (show all 39824)
# Title Authors PMID Year
1
Screening of 336 single-nucleotide polymorphisms in 85 obesity-related genes revealed McKusick-Kaufman syndrome gene variants are associated with metabolic syndrome. 62 57
19247371 2009
2
Hepatic insulin resistance directly promotes formation of cholesterol gallstones. 62 57
18587407 2008
3
Variants in the CD36 gene associate with the metabolic syndrome and high-density lipoprotein cholesterol. 62 57
18305138 2008
4
Brain glucose metabolism controls the hepatic secretion of triglyceride-rich lipoproteins. 62 57
17273170 2007
5
The metabolic syndrome resulting from a knockout of the NEIL1 DNA glycosylase. 62 57
16446448 2006
6
Retinoid x receptor heterodimers in the metabolic syndrome. 62 57
16093469 2005
7
Association of the metabolic syndrome with intracranial atherosclerotic stroke. 62 57
16043803 2005
8
Association between the PPARalpha-L162V polymorphism and components of the metabolic syndrome. 62 57
15309680 2004
9
Evidence for substantial effect modification by gender in a large-scale genetic association study of the metabolic syndrome among coronary heart disease patients. 62 57
14557872 2003
10
Association of low interleukin-10 levels with the metabolic syndrome in obese women. 62 57
12629085 2003
11
The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. 62 57
12588201 2003
12
Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. 62 57
11790215 2002
13
A transgenic model of visceral obesity and the metabolic syndrome. 62 57
11739957 2001
14
A genome-wide scan for coronary heart disease suggests in Indo-Mauritians a susceptibility locus on chromosome 16p13 and replicates linkage with the metabolic syndrome on 3q27. 62 57
11734540 2001
15
Cardiovascular morbidity and mortality associated with the metabolic syndrome. 62 57
11315831 2001
16
Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome. 62 57
11121050 2000
17
Prospective analysis of the insulin-resistance syndrome (syndrome X). 53 57
1587398 1992
18
Linkage and potential association of obesity-related phenotypes with two genes on chromosome 12q24 in a female dizygous twin cohort. 57
16391564 2006
19
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. 62 46
16459310 2006
20
A common functional exon polymorphism in the microsomal triglyceride transfer protein gene is associated with type 2 diabetes, impaired glucose metabolism and insulin levels. 57
16721486 2006
21
Association between common polymorphisms of the proopiomelanocortin gene and body fat distribution: a family study. 57
16046320 2005
22
Protein tyrosine phosphatase 1B variant associated with fat distribution and insulin metabolism. 57
15919835 2005
23
Effects of peroxisome proliferator-activated receptor-gamma 2 Pro12Ala polymorphism on body fat distribution in female Korean subjects. 57
15562396 2004
24
Association of polymorphisms in the estrogen receptor alpha gene with body fat distribution. 57
12917706 2003
25
Plasma adiponectin levels and blood pressures in nondiabetic adolescent females. 57
12970275 2003
26
Metabolic implications of body fat distribution. 57
1773700 1991
27
Banting lecture 1988. Role of insulin resistance in human disease. 57
3056758 1988
28
Modulation of 11beta-hydroxysteroid dehydrogenase type 1 activity by 1,5-substituted 1H-tetrazoles. 53 62
20452767 2010
29
MiR-33 contributes to the regulation of cholesterol homeostasis. 46
20466885 2010
30
Peroxisome proliferator-activated receptor-delta genotype influences metabolic phenotype and may influence lipid response to statin therapy in humans: a genetics of diabetes audit and research Tayside study. 53 62
20200337 2010
31
Obesity and corticosteroids: 11beta-hydroxysteroid type 1 as a cause and therapeutic target in metabolic disease. 53 62
19804814 2010
32
Tetrahydrobiopterin responsiveness after extended loading test of 12 Danish PKU patients with the Y414C mutation. 53 62
20063067 2010
33
Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. 53 62
19825813 2010
34
Different clinical presentation in siblings with mitochondrial acetoacetyl-CoA thiolase deficiency and identification of two novel mutations. 53 62
20046049 2010
35
The metabolic syndrome in South Asians: epidemiology, determinants, and prevention. 53 62
19900153 2009
36
Pathomechanisms of type 2 diabetes genes. 53 62
19749172 2009
37
Heme regulation of human cystathionine beta-synthase activity: insights from fluorescence and Raman spectroscopy. 53 62
19722721 2009
38
Altered body composition in preterm infants at hospital discharge. 53 62
19594474 2009
39
The lipin family: mutations and metabolism. 53 62
19369868 2009
40
Biochemical and biophysical analysis of five disease-associated human adenylosuccinate lyase mutants. 53 62
19405474 2009
41
2008 Landis Award lecture. Inflammation and the autodigestion hypothesis. 53 62
19384726 2009
42
AMPK: an emerging drug target for diabetes and the metabolic syndrome. 53 62
19416711 2009
43
GLUT2 mutations, translocation, and receptor function in diet sugar managing. 53 62
19223655 2009
44
[Metabolic syndrome and hormonal interaction in obese and type 2 diabetic Algerian subject: the behavior eating disorder impact]. 53 62
19411234 2009
45
The role and regulation of 11beta-hydroxysteroid dehydrogenase type 1 in the inflammatory response. 53 62
18973788 2009
46
Adipogenic risk factor differences between Korean and white adults--potential role of plasma free fatty acid and adiponectin. 53 62
19154962 2009
47
Neurological manifestations of acute intermittent porphyria. 53 62
19268005 2009
48
Children's toxicology from bench to bed--Liver Injury (4): Mitochondrial respiratory chain disorder and liver disease in children. 53 62
19571475 2009
49
[Knee ochronotic arthropathy and arthroscopic findings]. 53 62
19293619 2009
50
Silencing of Abcd1 and Abcd2 genes sensitizes astrocytes for inflammation: implication for X-adrenoleukodystrophy. 53 62
18723473 2009

Variations for Abdominal Obesity-Metabolic Syndrome 1

Copy number variations for Abdominal Obesity-Metabolic Syndrome 1 from CNVD:

6
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 267520 mtDNA 1 16569 Copy number Metabolic syndrome

Expression for Abdominal Obesity-Metabolic Syndrome 1

Search GEO for disease gene expression data for Abdominal Obesity-Metabolic Syndrome 1.

Pathways for Abdominal Obesity-Metabolic Syndrome 1

Pathways related to Abdominal Obesity-Metabolic Syndrome 1 according to GeneCards Suite gene sharing:

(show all 28)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.74 ADIPOQ APOB GCG HSD11B1 INS LPL
2
Show member pathways
12.75 SLC2A4 RETN LEP INS ADIPOQ
3
Show member pathways
12.65 SLC2A4 SCD PPARD PPARA IGFBP1
4
Show member pathways
12.52 SCD PPARG PPARA LPL INS HSD11B1
5
Show member pathways
12.44 SLC2A4 PPARG PPARA LPL LEP ADIPOQ
6 12.29 ADIPOQ GCG IGFBP1 INS PPARG SCD
7
Show member pathways
12.01 SLC2A4 LEP INS ADIPOQ
8
Show member pathways
11.89 PPARG PPARD PPARA
9
Show member pathways
11.76 SLC2A4 PPARG ADIPOQ
10
Show member pathways
11.68 APOB LPL MIR33A MTTP
11
Show member pathways
11.63 MTTP LPL APOB
12 11.61 SLC2A4 PPARG LPL LEP INS ADIPOQ
13 11.59 SERPINE1 LEP IGFBP1
14 11.48 SLC2A4 SERPINE1 SCD RETN PPARG PPARD
15 11.42 PPARG PPARD PPARA
16 11.4 PPARA LEP INS ADIPOQ
17
Show member pathways
11.38 LPL INS IGFBP1
18
Show member pathways
11.37 SCD PPARG PPARD PPARA LPL ADIPOQ
19 11.28 INS GCG APOB
20 11.21 PPARG PPARD PPARA MIR33A
21 11.12 PPARG PPARA LPL
22 11.08 PPARG LEP ADIPOQ
23 10.97 SLC2A4 PPARG LEP ADIPOQ
24 10.92 SLC2A4 INS
25 10.86 SLC2A4 INS
26 10.83 SCD PPARA
27 10.36 SLC2A4 PPARD GCG
28 10.16 PPARD PPARA

GO Terms for Abdominal Obesity-Metabolic Syndrome 1

Cellular components related to Abdominal Obesity-Metabolic Syndrome 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum lumen GO:0005788 9.65 MTTP INS IGFBP1 GCG APOB
2 extracellular space GO:0005615 9.6 SERPINE1 RETN MIR122 LPL LEP INS

Biological processes related to Abdominal Obesity-Metabolic Syndrome 1 according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of inflammatory response GO:0050728 10.2 PPARG PPARD PPARA ADIPOQ
2 response to ethanol GO:0045471 10.19 ADIPOQ LEP PPARA SLC2A4
3 cellular response to insulin stimulus GO:0032869 10.18 SLC2A4 PPARG LEP ADIPOQ
4 fatty acid metabolic process GO:0006631 10.15 LPL PPARA PPARD PPARG SCD
5 positive regulation of fat cell differentiation GO:0045600 10.13 PPARG PPARD LPL
6 fatty acid beta-oxidation GO:0006635 10.11 PPARD LEP ADIPOQ
7 hormone-mediated signaling pathway GO:0009755 10.1 PPARG PPARD PPARA
8 lipid metabolic process GO:0006629 10.1 SCD PPARG PPARD MTTP LPL LEP
9 regulation of lipid metabolic process GO:0019216 10.09 PPARA PPARD PPARG
10 glucose metabolic process GO:0006006 10.08 PPARD LEP INS ADIPOQ
11 response to nutrient GO:0007584 10.06 PPARG LEP ADIPOQ
12 placenta development GO:0001890 10.02 LEP PPARD PPARG
13 negative regulation of miRNA transcription GO:1902894 10.02 PPARA PPARD PPARG
14 lipoprotein transport GO:0042953 10.01 PPARG MTTP APOB
15 response to activity GO:0014823 10.01 ADIPOQ GCG LEP PPARD
16 intracellular receptor signaling pathway GO:0030522 10 PPARG PPARD PPARA
17 response to lipid GO:0033993 9.99 PPARG PPARD PPARA
18 negative regulation of lipid storage GO:0010888 9.97 PPARG LEP
19 negative regulation of appetite GO:0032099 9.96 PPARA LEP
20 lipoprotein metabolic process GO:0042157 9.96 PPARA MTTP APOB
21 positive regulation of cholesterol storage GO:0010886 9.95 LPL APOB
22 negative regulation of sequestering of triglyceride GO:0010891 9.92 PPARG PPARA
23 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.91 PPARG PPARA ADIPOQ
24 negative regulation of feeding behavior GO:2000252 9.89 RETN INS
25 negative regulation of cholesterol storage GO:0010887 9.85 PPARG PPARD PPARA
26 response to organic substance GO:0010033 9.82 PPARG PPARD APOB
27 negative regulation of acute inflammatory response GO:0002674 9.82 INS PPARG
28 cell communication GO:0007154 9.81 PPARG PPARD PPARA
29 glucose homeostasis GO:0042593 9.77 SLC2A4 PPARG MIR33A LEP INS GCG
30 fatty acid oxidation GO:0019395 9.76 PPARG PPARD ADIPOQ
31 cellular response to prostaglandin stimulus GO:0071379 9.74 PPARG APOB
32 regulation of fat cell differentiation GO:0045598 9.7 PPARG PPARD LEP
33 positive regulation of fatty acid oxidation GO:0046321 9.65 PPARA PPARD PPARG
34 cellular response to stimulus GO:0051716 9.33 PPARG PPARD PPARA
35 positive regulation of fatty acid metabolic process GO:0045923 9.23 PPARG PPARD PPARA ADIPOQ

Molecular functions related to Abdominal Obesity-Metabolic Syndrome 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nuclear receptor activity GO:0004879 9.73 PPARG PPARD PPARA
2 signaling receptor binding GO:0005102 9.7 SERPINE1 LPL LEP IGFBP1 GCG ADIPOQ
3 transcription coactivator binding GO:0001223 9.55 PPARG PPARD PPARA
4 hormone activity GO:0005179 9.32 RETN LEP INS GCG ADIPOQ

Sources for Abdominal Obesity-Metabolic Syndrome 1

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....